Vericel Current Ratio 2006-2021 | VCEL

Vericel current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Vericel Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.14B $0.02B 5.81
2021-03-31 $0.13B $0.02B 5.48
2020-12-31 $0.12B $0.02B 5.50
2020-09-30 $0.13B $0.02B 5.88
2020-06-30 $0.12B $0.02B 6.39
2020-03-31 $0.12B $0.02B 6.43
2019-12-31 $0.11B $0.02B 5.64
2019-09-30 $0.11B $0.02B 6.93
2019-06-30 $0.09B $0.01B 7.50
2019-03-31 $0.11B $0.01B 8.47
2018-12-31 $0.11B $0.02B 7.63
2018-09-30 $0.12B $0.02B 7.96
2018-06-30 $0.12B $0.02B 7.72
2018-03-31 $0.05B $0.01B 3.47
2017-12-31 $0.05B $0.01B 3.86
2017-09-30 $0.04B $0.02B 2.50
2017-06-30 $0.03B $0.01B 2.55
2017-03-31 $0.04B $0.02B 2.51
2016-12-31 $0.05B $0.01B 3.48
2016-09-30 $0.02B $0.02B 1.37
2016-06-30 $0.02B $0.01B 1.95
2016-03-31 $0.03B $0.01B 1.88
2015-12-31 $0.03B $0.01B 2.26
2015-09-30 $0.03B $0.01B 3.08
2015-06-30 $0.03B $0.01B 3.10
2015-03-31 $0.04B $0.01B 3.00
2014-12-31 $0.04B $0.01B 3.51
2014-09-30 $0.05B $0.01B 3.58
2014-06-30 $0.01B $0.02B 0.83
2014-03-31 $0.01B $0.01B 1.51
2013-12-31 $0.01B $0.01B 1.59
2013-09-30 $0.01B $0.01B 1.57
2013-06-30 $0.01B $0.00B 1.23
2013-03-31 $0.01B $0.00B 2.23
2012-12-31 $0.01B $0.01B 2.47
2012-09-30 $0.02B $0.01B 3.08
2012-06-30 $0.03B $0.01B 2.43
2012-03-31 $0.04B $0.02B 1.67
2011-12-31 $0.01B $0.02B 0.30
2011-09-30 $0.01B $0.03B 0.50
2011-06-30 $0.02B $0.03B 0.63
2011-03-31 $0.03B $0.03B 0.91
2010-12-31 $0.03B $0.03B 1.06
2010-09-30 $0.02B $0.00B 4.30
2010-06-30 $0.02B $0.00B 7.34
2010-03-31 $0.02B $0.00B 12.95
2009-12-31 $0.02B $0.00B 7.43
2009-09-30 $0.02B $0.00B 9.00
2009-06-30 $0.02B $0.00B 10.55
2009-03-31 $0.02B $0.00B 11.87
2008-12-31 $0.02B $0.00B 9.18
2008-09-30 $0.02B $0.00B 10.86
2008-06-30 $0.02B $0.00B 11.46
2008-03-31 $0.03B $0.00B 15.60
2007-12-31 $0.03B $0.00B 15.51
2007-09-30 $0.03B $0.00B 7.63
2007-06-30 $0.03B $0.00B 8.62
2007-03-31 $0.03B $0.00B 14.47
2006-12-31 $0.04B $0.00B 15.95
2006-09-30 $0.04B $0.00B 18.65
2006-06-30 $0.04B $0.00B 17.20
2006-03-31 $0.02B $0.00B 13.54
2005-12-31 $0.03B $0.00B 19.67
2005-09-30 $0.03B $0.00B 23.09
2005-06-30 $0.03B $0.00B 38.14
2005-03-31 $0.04B $0.00B 45.43
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.392B $0.124B
Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76